Let’s dig into the relative performance of Clover Health (NASDAQ:CLOV) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.

Clover Health Investments has delivered a very strong 227.7% return over the past 3 years, yet the share price around US$4.49 now lines up with valuation checks that suggest the stock no longer looks obviously cheap or clearly expensive. With the broader metrics pointing to an overall high value score, the current level raises the question of whether the recent gains still leave enough room for further upside. Clover Health Investments' 227.7% share price gain over 3 years sets a high bar...

Clover Health Investments, Corp. has already reported its second-quarter 2026 results, posting revenue of US$743.17 million versus US$477.62 million a year earlier and moving from a net loss of US$10.58 million to net income of US$28 million. Alongside this shift to profitability, the company highlighted strong Medicare Advantage membership growth and benefits from its AI-powered Clover Assistant platform, which management views as central to supporting future operational and financial...

Clover Health’s second quarter results were met with a positive market reaction, driven by strong Medicare Advantage membership growth and improved profitability. Management credited the quarter’s performance to the expansion of its Clover Assistant AI platform and disciplined focus on core markets, particularly New Jersey and Georgia. CEO Andrew Toy emphasized that “better clinical care leads to stronger cohort economics,” pointing to the impact of maturing member cohorts under the company’s te

Medicare Advantage membership surged 48% as profitability improved sharply.

Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation. Thornton said the company’s goal is to equip

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

Moby summary of Clover Health Investments, Corp.'s Q2 2026 earnings call

Clover Health Investments Corp (CLOV) delivers robust Q2 2026 results with improved underwriting and expanding non-insurance businesses, driving a confident full-year outlook.

Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures. Chief Executive Officer Andrew Toy said the company views its Clove

Health insurance company Clover Health (NASDAQ:CLOV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 55.6% year on year to $743.2 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 1.7% above analysts’ estimates. Its GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

After years of burning cash and testing investor patience, Clover Health just posted results that bulls have been waiting for. But with medical costs creeping up and the stock already priced for perfection, the real question is whether this milestone is a turning point or a trap.

Toy retains a $44.68 million direct stake after the non-discretionary sale triggered by RSU vesting. Remaining tranches vest quarterly through October 2028, signaling predictable future sell-to-cover activity.

Clover Health Investments said in a regulatory filing on Friday that it ‌detected unusual login activity on some of its ‌information systems on July 4 and later found a hacker had ​gained access to three employee accounts through social engineering. • The health insurer said the affected accounts belonged to non-managerial health plan employees who handled member visit ‌scheduling and broker-facing sales ⁠work. • These accounts could access some personal and protected health information, according to the ⁠company, but not corporate financial or claims systems.